ClinicalTrials.gg
Not yet recruitingNCT07951320RESET-PsOUpdated Nov 20, 2026

Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors

A Phase 2 interventional study of Background IL-17A Inhibitor Therapy and Recaticimab in Plaque Psoriasis and Dyslipidemia, sponsored by Xiangya Hospital of Central South University. Not yet recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Xiangya Hospital of Central South University · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 75 studies in Dyslipidemias with a site in China — 23 open to participants now, 33 under way, 10 of them phase 3. Dyslipidemias · China.

Planned enrollment
40th of 58
100 · median 210
Started
2026
with 8 others
Phase 2
6 of 75
4 open now
Primary completion
2028-04
later than 25 of 32 live
Registered
75th of 75
by date

Among the 75 studies in Dyslipidemias with a site in China, this one is the 40th largest by planned enrollment of the 58 interventional ones that give a count, is one of 9 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 25 of the 32 other live ones, and was the 75th registered.

Dyslipidemias

1,251 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 75 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Dyslipidemias with a site in China, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.

Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.

Both groups receive recaticimab after the Week 16 assessments through Week 32, with safety follow-up at Week 36.

Read the detailed description

After screening of up to 4 weeks, participants are randomized 1:1 to recaticimab or matching placebo while continuing their established IL-17A inhibitor regimen.

Recaticimab 150 mg or matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After the Week 16 efficacy assessments, both groups receive recaticimab 150 mg at Weeks 16, 20, 24, 28, and 32. Safety follow-up is at Week 36, without study-drug administration. Post-Week 16 comparisons are exploratory.

A prespecified interim analysis may increase total enrollment from 100 to a maximum of 150 participants.

03

Conditions studied

  • Plaque Psoriasis
  • Dyslipidemia

Browse trials for

Keywords

  • IL-17A Inhibitor
  • Recaticimab
  • PCSK9 Inhibitor
  • Dyslipidemia
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

  1. Understand the study requirements and procedures, voluntarily provide written , and be willing and able to comply with the protocol.
  2. Be male or female and aged 18 to 75 years, inclusive.
  3. Have a clinical diagnosis of plaque psoriasis that was moderate to severe before starting the current interleukin-17A (IL-17A) inhibitor.
  4. Meet the following prior-treatment and prior-response requirements for secondary treatment failure:

    Moderate-to-severe plaque psoriasis before starting the current IL-17A inhibitor must be supported by contemporaneous medical records. The investigator must verify the severity classification and its basis with reference to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 edition).

    The total duration of treatment with the current IL-17A inhibitor before enrollment must be at least 16 weeks. The actual cumulative dose received must be at least 80% of the cumulative dose calculated according to the product-label-recommended regimen over the same treatment period.

    A prior good clinical response during treatment with this drug must be supported by verifiable medical records and meet at least one of the following four conditions:

    1. Recorded Psoriasis Area and Severity Index (PASI) scores demonstrate a reduction of at least 90% from the PASI score before starting that IL-17A inhibitor, corresponding to a PASI90 response.
    2. Contemporaneous medical records document a static Physician's Global Assessment (sPGA) or Investigator's Global Assessment (IGA) score of 0 or 1, with these categories corresponding to clear or almost clear on the scale used.
    3. Contemporaneous physician records explicitly document clear or almost clear skin lesions.
    4. Contemporaneous medical records document that the percentage of body surface area affected by psoriasis (BSA) decreased to 1% or less during treatment with the same current IL-17A inhibitor.

    The requirement for documented moderate-to-severe disease before treatment applies to all four pathways. Available pretreatment PASI, BSA, sPGA/IGA, Dermatology Life Quality Index (DLQI), and clinical severity assessments must be recorded; all four scales are not required. The PASI90 pathway requires PASI values from both before and during treatment with that drug. Each other pathway requires the relevant on-treatment record and evidence of moderate-to-severe disease before treatment. The investigator must verify the drug, dates, overall skin involvement, and source of evidence. Patient recall alone or a history of biologic use alone is insufficient. Missing historical scores must not be reconstructed.

  5. After achieving at least one of the good-response criteria above, have subsequent worsening while continuing the same IL-17A inhibitor, with PASI ≥3 and sPGA ≥2 at both screening and the Week 0 baseline visit, and an investigator judgment that a change in treatment strategy is needed. The investigator must review the prior response, worsening, and treatment records to confirm their temporal sequence and determine that the current worsening is not primarily attributable to treatment interruption or substantial nonadherence.
  6. Have dyslipidemia with fasting low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L and \<4.9 mmol/L, without atherosclerotic cardiovascular disease (ASCVD).
  7. Women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. Male and female participants of must agree to use highly effective throughout the study and for 30 days after the last dose of study drug. Participants must also comply with the contraception requirements for their background IL-17A inhibitor. Any longer contraception periods specified in the applicable prescribing information or investigator's brochure must also be observed.
  8. Be willing to complete the required protocol examinations and assessments. Participation in optional assessments is voluntary, and declining them does not affect eligibility for the main study.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria are excluded:

  1. A diagnosis of non-plaque psoriasis at screening or baseline, including guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis.
  2. Severe to an active ingredient or any of the study drugs.
  3. Concomitant .
  4. Any previous or current PCSK9-targeted therapy, including PCSK9 monoclonal antibodies or PCSK9-targeting small interfering RNA (siRNA) drugs, such as inclisiran.
  5. Current treatment at screening with other lipid-lowering drugs, such as statins or ezetimibe. Clinically necessary lipid-lowering treatment must not be discontinued to meet study eligibility criteria.
  6. Treatment with a biologic targeting a pathway other than IL-17A, or a small-molecule targeted drug, within 4 weeks before screening.
  7. active disease, such as active tuberculosis or active hepatitis.
  8. Participation in another clinical trial with use of a trial-related drug within 3 months before screening.
  9. Pregnancy, breastfeeding, or planned pregnancy during the study; or unwillingness of a male or female participant to use .
  10. Major surgery within 3 months before screening or planned major surgery during the study.
  11. Renal impairment with an estimated (eGFR) \<30 mL/min/1.73 m² during screening.
  12. (ALT) or aspartate aminotransferase (AST) >3 times the (ULN), or total >2 times ULN.
  13. (NYHA) class III or IV heart failure, or \<30%.
  14. Previously or currently diagnosed ASCVD, including coronary heart disease, ischemic stroke, or atherosclerotic peripheral artery disease; or another type of stroke within 3 months before randomization.
  15. A need to promptly initiate, continue, or intensify lipid-lowering drug therapy, based on an assessment of overall ASCVD risk and lipid-lowering treatment needs according to the Chinese Guidelines for Lipid Management (2023), such that treatment should not be delayed during the 16-week controlled treatment period.
  16. Any other condition that, in the investigator's judgment, makes participation inappropriate.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Recaticimab Plus Background IL-17A Inhibitor

    Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants receive recaticimab 150 mg subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.

    Drug: Background IL-17A Inhibitor Therapy · Drug: Recaticimab

  • Placebo comparator
    Placebo Plus Background IL-17A Inhibitor

    Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants switch to recaticimab 150 mg administered subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.

    Drug: Background IL-17A Inhibitor Therapy · Drug: Recaticimab · Drug: Matching Placebo

Interventions

  • DrugBackground IL-17A Inhibitor Therapy

    Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency.

  • Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments.

  • DrugMatching Placebo

    Matching placebo is administered subcutaneously to participants assigned to the placebo comparator arm at Weeks 0, 4, 8, and 12 during the double-blind, placebo-controlled period.

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving PASI75 at Week 16

    PASI75 is defined as a ≥75% reduction in the Psoriasis Area and Severity Index (PASI) score from the Week 0 randomization baseline.

    Time frame: Week 16

Secondary outcomes

  1. Mean percentage improvement from baseline in sPGA × BSA at Week 16

    sPGA × BSA is the sPGA score multiplied by affected BSA (%). Mean individual percentage improvement is calculated as 100 × (Week 0 value - Week 16 value) / Week 0 value.

    Time frame: Baseline (Week 0) and Week 16

  2. Mean change from baseline in PASI score

    Mean change from the Week 0 PASI score. PASI ranges from 0 to 72; higher scores indicate more severe disease.

    Time frame: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  3. Mean percentage improvement from baseline in PASI score

    Mean of individual percentage improvements in PASI: 100 × (Week 0 score - post-baseline score) / Week 0 score. Higher values indicate greater improvement.

    Time frame: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  4. Percentage of participants achieving PASI50

    Percentage with at least a 50% reduction in PASI from the Week 0 randomization baseline.

    Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  5. Percentage of participants achieving PASI90

    Percentage with at least a 90% reduction in PASI from the Week 0 randomization baseline.

    Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  6. Percentage of participants achieving PASI100

    Percentage with a 100% reduction in PASI from the Week 0 randomization baseline.

    Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  7. Percentage of participants with sPGA 0 or 1

    Percentage with a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). The scale ranges from 0 to 4.

    Time frame: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  8. Change from baseline in skin itch Numeric Rating Scale score

    Change from Week 0 in skin itch Numeric Rating Scale (NRS) score, ranging from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

  9. Change from baseline in Dermatology Life Quality Index score

    Change from the last valid pre-dose Dermatology Life Quality Index (DLQI) score. Scores range from 0 to 30; higher scores indicate worse quality of life.

    Time frame: Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36

  10. Percentage change from baseline in low-density lipoprotein cholesterol

    Percentage change in LDL-C: 100 × (post-baseline - baseline) / baseline. Baseline is the last valid pre-dose measurement.

    Time frame: Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32

  11. Participants with treatment-emergent adverse events

    Number and percentage of participants with adverse events occurring after the first study dose through the final safety follow-up visit.

    Time frame: From the first study dose through Week 36

07

Study locations

7 sites
08

References and documents

Publications

  • Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, Honarpour N, Keech AC, Sever PS, Sabatine MS, Giugliano RP. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025 May 20;151(20):1467-1476. doi: 10.1161/CIRCULATIONAHA.124.072756. Epub 2025 Apr 21. PubMed 40255182 ↗
  • Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025 Jan;92(1):92-99. doi: 10.1016/j.jaad.2024.09.031. Epub 2024 Sep 26. PubMed 39332633 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 43 phase 2 interventional studies under Dyslipidemias, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 10, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951320
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Yi Xiao
Contact
xiaoyixy@csu.edu.cn
+86 137 8719 1233
Yehong Kuang
Contact
yh_927@126.com
+86 13574171102

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recaticimab

Start the discussion